Macro Group Pharmaceutical S.A.E.

Macro Group Pharmaceutical S.A.E.

EEGX:MCRO
1.29
EGP
-0.06
(-4.44%)
0.06EPS
18.63P/E
4.11BMarket Cap
Macro Group Pharmaceutical S.A.E.
EGX:MCRO
(Egyptian Exchange)

Recent

price

1.29

P/E

ratio

18.63

div

yld

- -

ROIC.AI

2020
2021
2022
TTM
EGP
0.16
0.22
0.28
0.42
Revenue per Share
0.05
0.06
0.07
0.06
Basic EPS, GAAP
0.01
0.02
0.05
-0.01
Free Cash Flow per Basic Share
0.03
0.02
0.02
- -
Dividend per Share
- -
0.14
0.17
0.24
Book Value per Share
- -
0.12
0.16
0.23
Tangible Book Value per Share
2,647
2,647
2,624
2,574
Basic Weighted Avg Shares
431
594
730
1,069
Sales/Revenue/Turnover
42.88
34.35
32.55
17.74
Operating Margin (%)
2
7
14
21
Depreciation Expense
135
148
174
166
Net Income, GAAP
23.94
24.68
23.52
13.59
Effective Tax Rate (%)
31.39
24.89
23.83
15.51
Profit Margin (%)
- -
270
366
707
Working Capital
- -
11
21
38
LT Debt
- -
358
463
822
Total Equity
- -
- -
31.21
23.99
Return on Invested Capital (%)
- -
- -
34.91
28.57
Return on Capital (%)
- -
- -
42.36
35.97
Return on Common Equity (%)

Capital Structure

EGP

•

in mil. unless spec.
Sep'23
Mar'23
Jun'23
ST Debt
196
13
12
LT Borrowings
85
- -
- -
LT Finance Leases
8
30
38
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,614
3,421
3,421
Market Capitalization
1,619
4,653
4,105

Working Capital

EGP

•

in mil. unless spec.
Sep'23
Mar'23
Jun'23
Total Current Assets
675
1,029
1,111
Cash, Cash Equivalents & STI
122
476
480
Accounts Receivable, Net
136
76
118
Inventories
92
138
159
Total Current Liabilities
503
346
403
Payables & Accruals
- -
- -
- -
ST Debt
196
13
12
Deferred Revenue
- -
- -
- -

Growth Rates

EGP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
29.34%
Free Cash Flow
- -
- -
183.79%
Net Income, GAAP
- -
- -
17.51%
Sales/Revenue/Turnover
- -
- -
22.78%
Total Cash Common Dividend
- -
- -
-14.57%

Quarterly Revenue

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

EGP

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Business
Macro Group Pharmaceutical S.A.E. is an Egypt-based healthcare and cosmeceuticals company primarily engaged in the development, manufacture, marketing, and distribution of cosmeceutical products, dermatological solutions, and nutraceutical dietary supplements. Founded in 2005 and headquartered in Cairo, Egypt, the company operates across specialized therapeutic and personal care segments targeting medical professionals, retail pharmacies, and consumers. The company's product portfolio is organized across several core categories, including dermatological and skincare formulations, comprising anti-scarring treatments, anti-acne preparations, skin-lightening creams, intensive moisturizers, and anti-aging serums under brands such as Scaro, Sebaclar, Melatex, and Urepar; hair care products, including therapeutic anti-hair loss treatments, revitalizing shampoos, and hair oils marketed under the Atrakta brand; oral care solutions, consisting of antiseptic and therapeutic mouthwashes and specialty toothpastes under the Orovex brand; feminine hygiene preparations, including topical cleansing and antiseptic washes under the Gold brand; sun protection products, providing broad-spectrum ultraviolet protective creams and lotions; and nutraceuticals, including vitamins, mineral formulations, and immune-support dietary supplements. In addition to proprietary branded products, the company provides toll manufacturing and contract packaging services for third-party pharmaceutical and personal care enterprises through its manufacturing facility located in Badr City, Egypt. Macro Group Pharmaceutical S.A.E. conducts its primary commercial operations in Egypt, supported by a specialized medical sales force engaging physicians across dermatology, pediatrics, gynecology, and dentistry disciplines, alongside widespread distribution to wholesale and retail pharmacies. The company also exports its formulations to regional markets across the Middle East, North Africa, and Sub-Saharan Africa, including Saudi Arabia, the United Arab Emirates, Iraq, Libya, and Sudan. In recent operational developments, Macro Group Pharmaceutical S.A.E. has expanded its product pipeline with the launch of new over-the-counter dietary supplements and specialized clinical skincare lines. The company has implemented production capacity upgrades and automation enhancements at its Badr City manufacturing complex to support rising export demand. Additionally, Macro Group has advanced its international growth strategy by entering new regional distribution partnerships across the Gulf Cooperation Council (GCC) and select African markets, while expanding its domestic commercial reach through omnichannel pharmacy partnerships and digital health platforms.